Who are Protagonist Therapeutics, Inc.'s main suppliers?

Protagonist Therapeutics, Inc. (PTGX) key suppliers include: CONTRACT-MANUFACTURERS, Johnson & Johnson, Johnson & Johnson, MoonLake Immunotherapeutics, Rani Therapeutics Holdings, Inc. and 2 more. View the full supplier network at chainsifter.com/chain/PTGX.

Who are Protagonist Therapeutics, Inc.'s major customers?

Protagonist Therapeutics, Inc. (PTGX) key customers include: Johnson & Johnson, Johnson & Johnson, Rani Therapeutics Holdings, Inc., CAPITAL-RESOURCES, DELAWARE-GENERAL-CORPORATION and 2 more. View the full customer network at chainsifter.com/chain/PTGX.

What sector is Protagonist Therapeutics, Inc. in?

Protagonist Therapeutics, Inc. (PTGX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Protagonist Therapeutics, Inc. Supplier List (PTGX): 7 Verified Suppliers

7Suppliers

7Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Protagonist Therapeutics, Inc. (PTGX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

3Distinct source URLs

7High confidence

0.770Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Protagonist Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CONTRACT-MANUFACTURERS	CONTRACT-MANUFACTURERS	90%	We also rely on our contract manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials.
JNJ	Johnson & Johnson	72%	ld negatively impact our business. ● If our partners do not satisfy their obligations under our agreements with them, or if they terminate our partnerships with them, we may not be able to develop or…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: ld negatively impact our business. ● …
MLTX	MoonLake Immunotherapeutics	72%	Reciprocal relationship from MLTX graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from MLTX graph: LK through Phase 3 development and regulatory approval will require us to ex…
RANI	Rani Therapeutics Holdings, Inc.	72%	Reciprocal relationship from RANI graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. …
ZLDPF	Zealand Pharma A/S	72%	s and Other Commitments In the normal course of business, we enter into agreements with contract service providers to assist in the performance of our research and development activities and clinical…
ZLDPF	Zealand Pharma A/S	72%	Reciprocal relationship from ZLDPF graph: Reciprocal relationship from PTGX graph: s and Other Commitments In the normal course of business, we enter into agreements with contract service providers t…

Protagonist Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
JNJ	Johnson & Johnson	92%	The Company has earned a total of $ 387.5 million in non-refundable payments from JNJ under the JNJ License and Collaboration Agreement
JNJ	Johnson & Johnson	92%	Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from JNJ grap…
RANI	Rani Therapeutics Holdings, Inc.	72%	Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain not…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	clinical programs, including progressing our product development candidates PN-881, PN-477, PN-458 and PN-8047 through IND-enabling studies, or foreign equivalents. The process of conducting research…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	de whole with respect to a future bank failure, account holders’ access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in t…
JANSSEN-BIOTECH-INC	JANSSEN-BIOTECH-INC	62%	ve date of the contract through December 31, 2024. The Company determined that the Takeda Collaboration Agreement met the definition of a collaborative arrangement under ASC Topic 808. Both parties…
TAKEDA-PHARMACEUTICALS-USA-INC	TAKEDA-PHARMACEUTICALS-USA-INC	62%	Item 1A, “ Risk Factors” and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC, before making an investment decisio…

Protagonist Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PTGX-DEBT-11934	Warrants outstanding: 1500000	90%	xbrl warrant detail from xbrl 2026-03-31.
PTGX-DEBT	Debt stack $9.8M	90%	Market cache reports total debt of $9.8M.
PTGX-DEBT-11935	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2016-12-31.

Protagonist Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
PTGX-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 325 tracked holders.

Protagonist Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ABBV	AbbVie Inc.	100.00	2
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
CLGN	CollPlant Biotechnologies Ltd.	100.00	2
ADGM	Adagio Medical Holdings, Inc.	100.00	2
AURA	Aura Biosciences, Inc.	100.00	2
ATON	AlphaTON Capital Corp	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
ACIU	AC Immune SA	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
SNNUF	Smith & Nephew plc	100.00	2
ALC	Alcon Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2

Protagonist Therapeutics, Inc. Supply Chain